At a Glance
- Company: Eli Lilly; Insilico Medicine (Hong Kong‑listed)
- Location: US (Lilly); Hong Kong/China (Insilico)
- Deal value: Up to $2.75 billion in milestones
- Focus area: AI‑generated therapies via Pharma.AI platform
- Next steps: Lilly advances portfolio including diabetes candidate
What happened?
Eli Lilly has signed a landmark deal worth up to $2.75 billion with Insilico Medicine for a portfolio of AI‑designed drug candidates generated by Insilico’s Pharma.AI platform. The agreement grants Lilly exclusive global rights to advance the programmes, marking one of the largest AI drug discovery partnerships to date.
Why does it matter?
The collaboration leverages Insilico’s generative AI to accelerate target identification and molecule design, potentially cutting discovery timelines and costs versus traditional methods. Lilly gains access to a pipeline including an oral diabetes candidate, bolstering its metabolic franchise amid GLP-1 dominance. It signals big pharma’s escalating bet on AI to replenish pipelines faster.
Who’s behind it?
Insilico Medicine, founded in 2014, pioneered end-to-end AI drug discovery with Pharma.AI, producing 28 candidates of which nearly half are in clinical trials. Eli Lilly, a leader in diabetes and obesity, continues aggressive AI investments to maintain edge.
How was it achieved?
Pharma.AI integrates generative models to identify novel targets and design optimised molecules, reducing pre-clinical timelines to ~18 months. The deal covers multiple assets, with Lilly handling development and commercialisation.
What’s next?
Lilly will prioritise clinical advancement of the portfolio, targeting diabetes and other areas. Insilico retains other programmes; success could validate AI’s role in reducing industry failure rates.
What are people saying?
Insilico: “Paradigm shift… higher success rates in trials.” Industry: “Eli Lilly positions at forefront of AI transformation.”